Figure 2 | Scientific Reports

Figure 2

From: CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor

Figure 2

Chidamide + celecoxib suppress tumor growth and enhance anti-PD-1-induced immunotherapy in an allograft CT26 mouse model. (A) CT26 tumor-bearing mice were orally administered a chidamide-k30 solution (CD, 50 mg/kg) once daily from days 10 to 25 (Day 10 mean TV, 240 ± 25 mm3), and celecoxib (C, 50 mg/kg) once daily from days 10 to 25. Arrows indicate the time points at which mice were treated with the anti-PD-1 antibody. The mice were treated with anti-PD-1 antibody (2.5 mg/kg, i.p.) once every 3 days on days 10, 13, 16, 19, 22, and 25. Endpoint tumor size is presented as fold change. Results are shown as mean ± standard deviation (SD). *p < 0.05 vs. anti-IgG; #p < 0.05 vs. anti-PD-1; &p < 0.05 vs. CD50 + C50. (B) Individual tumor growth graphs for CT26 tumor-bearing mice (n = 6–9). Number of tumor-free mice per total number of mice is shown at the top left corner of each panel. (C) Body weight of mice following each treatment was recorded. (D) Survival study of all the treatment groups.

Back to article page